Skip to content
← All treatment topics

TREATMENT READING

Childhood Vascular Tumors

Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.

Not medical advice · Not a complete treatment or trial directory

Made by Triangle.

Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.

57 sections
  1. Treatment Options Under Clinical Evaluation
  2. Special Considerations for the Treatment of Children With Cancer
  3. Treatment of infantile hemangioma
  4. Propranolol therapy
  5. Selective and other beta-blocker therapy
  6. Corticosteroid therapy
  7. Topical beta-blocker therapy
  8. Combined therapy for complicated hemangiomas
  9. Treatment options under clinical evaluation for infantile hemangiomas
  10. Treatment of spindle cell hemangioma
  11. Treatment of epithelioid hemangioma
  12. Treatment of pyogenic granuloma
  13. Treatment of angiofibroma
  14. Treatment of juvenile nasopharyngeal angiofibroma
  15. Treatment of kaposiform hemangioendothelioma and tufted angioma
  16. Treatment of uncomplicated kaposiform hemangioendothelioma and tufted angioma
  17. Treatment of complicated kaposiform hemangioendothelioma and tufted angioma
  18. Vincristine with or without steroid therapy
  19. Sirolimus with or without steroid therapy
  20. Supportive care and close monitoring of infants on sirolimus
  21. Surgical excision
  22. Long-term outcomes
  23. Treatment options under clinical evaluation for kaposiform hemangioendothelioma
  24. Treatment of pseudomyogenic hemangioendothelioma
  25. Treatment of retiform hemangioendothelioma
  26. Treatment of papillary intralymphatic angioendothelioma
  27. Treatment of composite hemangioendothelioma
  28. Treatment of Kaposi sarcoma
  29. Treatment of epithelioid hemangioendothelioma
  30. Treatment options under clinical evaluation for epithelioid hemangioendothelioma
  31. Treatment of angiosarcoma
  32. Surgery
  33. Radiation therapy
  34. Surgery, chemotherapy, and radiation therapy
  35. Palliative care
  36. Treatment options under clinical evaluation for angiosarcoma
  37. Treatment of infantile hemangioma
  38. Treatment of kaposiform hemangioendothelioma and tufted angioma
  39. Treatment of epithelioid hemangioendothelioma
  40. Treatment of angiosarcoma
  41. Types of treatment for childhood vascular tumors
  42. Who treats children with vascular tumors?
  43. Treatment options
  44. Beta-blocker therapy
  45. Surgery
  46. Photocoagulation
  47. Cryotherapy
  48. Embolization
  49. Chemotherapy
  50. Sclerotherapy
  51. Radiation therapy
  52. Targeted therapy
  53. Immunotherapy
  54. Other drug therapy
  55. Observation
  56. Clinical trials
  57. Side effects and late effects of treatment

Health professional · Vascular Malformations

Treatment Options Under Clinical Evaluation

Source: Childhood Vascular Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 17, 2025. Captured 2026-09-09.

Information about National Cancer Institute (NCI)-supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.

Sources: NCI website · ClinicalTrials.gov website

The following are examples of national and/or institutional clinical trials that are currently being conducted:

NCT04258046 (Trametinib in the Treatment of Complicated Extracranial Arterial Venous Malformation): This is a phase II study to assess the safety and efficacy of trametinib in the treatment of children and adults.

Sources: NCT04258046

NCT05125471 (Cobimetinib in Extracranial Arteriovenous Malformations [COBI-AVM Study]): This is a phase II study to evaluate the safety and efficacy of cobimetinib in the treatment of children and adults.

Sources: NCT05125471

NCT05948943 (Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Variant): This is a phase II/III study of adults and children (aged 6–17 years) that will determine the dose of alpelisib in stage 1, followed by confirmation of efficacy and safety in stage 2 of the study.

Sources: NCT05948943

This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.

Health professional

Special Considerations for the Treatment of Children With Cancer

Source: Childhood Vascular Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 17, 2025. Captured 2026-09-09.

Cancer in children and adolescents is rare, although the overall incidence has slowly increased since 1975.[1] Children and adolescents with cancer should be referred to medical centers that have a multidisciplinary team of cancer specialists with experience treating the cancers that occur during childhood and adolescence. This multidisciplinary team approach incorporates the skills of the following pediatric specialists and others to ensure that children receive treatment, supportive care, and rehabilitation to achieve optimal survival and quality of life:

Sources: 1

Primary care physicians.

Pediatric surgeons.

Transplant surgeons.

Pathologists.

Pediatric radiation oncologists.

Pediatric medical oncologists and hematologists.

Ophthalmologists.

Rehabilitation specialists.

Pediatric oncology nurses.

Social workers.

Child-life professionals.

Psychologists.

Nutritionists.

For specific information about supportive care for children and adolescents with cancer, see the summaries on Supportive and Palliative Care.

Sources: Supportive and Palliative Care

The American Academy of Pediatrics has outlined guidelines for pediatric cancer centers and their role in the treatment of children and adolescents with cancer.[2] At these centers, clinical trials are available for most types of cancer that occur in children and adolescents, and the opportunity to participate is offered to most patients and their families. Clinical trials for children and adolescents diagnosed with cancer are generally designed to compare potentially better therapy with current standard therapy. Other types of clinical trials test novel therapies when there is no standard therapy for a cancer diagnosis. Most of the progress in identifying curative therapies for childhood cancers has been achieved through clinical trials. Information about ongoing clinical trials is available from the NCI website.

Sources: 2 · NCI website

Dramatic improvements in survival have been achieved for children and adolescents with cancer.[3-5] Between 1975 and 2020, childhood cancer mortality decreased by more than 50%.[3,6,7] Childhood and adolescent cancer survivors require close monitoring because side effects of cancer therapy may persist or develop months or years after treatment. For specific information about the incidence, type, and monitoring of late effects in childhood and adolescent cancer survivors, see Late Effects of Treatment for Childhood Cancer.

Sources: 3 · 5 · 3 · 6 · 7 · Late Effects of Treatment for Childhood Cancer

Health professional · Benign Tumors / Infantile Hemangioma

Treatment of infantile hemangioma

Source: Childhood Vascular Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 17, 2025. Captured 2026-09-09.

The decision to treat patients with hemangiomas is based on several factors, including the following:[79]

Sources: 79

Size of the lesions.

Type of hemangioma.

Location of hemangioma.

Presence or risk of complications, including ulceration, possibility of scarring or disfigurement, the age of the patient, and the stage of growth of the hemangioma.

This decision is individualized among patients, and it is important to carefully consider the risks and benefits of treatment.

The American Academy of Pediatrics has published clinical practice guidelines on this topic. An early therapeutic intervention was noted to be critical for complex infantile hemangiomas to prevent medical complications and permanent disfigurement. The timing of interventions was noted to be best in the first 1 to 3 months of age. Photos were used to triage low-risk versus high-risk infantile hemangiomas,[80] and a scoring system was used for primary care physicians to encourage early referral to hemangioma specialists.[81] The guidelines indicated that hemangioma specialists are practitioners with expertise in the management and care of hemangiomas who have knowledge of risk stratification and treatment options. These providers consisted of experts in the fields of dermatology, hematology/oncology, pediatrics, plastic surgery, general surgery, otolaryngology, and ophthalmology.[82]

Sources: 80 · 81 · 82

Treatment options for infantile hemangioma include the following:

Propranolol therapy.

Sources: Propranolol therapy

Selective and other beta-blocker therapy.

Sources: Selective and other beta-blocker therapy

Corticosteroid therapy.

Sources: Corticosteroid therapy

Laser therapy.

Laser therapy.

Usually reserved for ulcerated infantile hemangiomas and residual lesions, such as telangiectasias after the proliferative period.[83] Pulsed dye laser therapy helps with pain from ulcerative infantile hemangiomas. The use of pulsed dye laser therapy as an up-front treatment for infantile hemangiomas is controversial.

Sources: 83

A Russian pilot study employed multiline laser equipment using the Nd:YAP Q-Sw/KTP emitters combined with two wavelengths of 1079/540 nm to treat patients with infantile hemangiomas.[84] Laser treatment was performed on 109 patients with 119 hemangiomas. Evaluation of posttreatment samples revealed restoration of normal color, skin relief, and the absence of scars.

Sources: 84

A retrospective study in China included 180 patients with superficial hemangiomas who were treated with a 595-nm pulsed dye laser. The study reported that younger children (aged <2 months) received fewer treatments, had shorter courses of disease, and experienced better effects with fewer adverse events when compared with older children.[85]

Sources: 85

Excisional surgery. With the advent of new medical treatments, the use of surgery is reserved for ulcerated lesions, residual lesions, large periocular lesions that interfere with vision, and facial lesions with aesthetic impact that do not respond to medical therapy.[86]

Sources: 86

Topical beta-blocker therapy.

Sources: Topical beta-blocker therapy

Combined therapy for complicated hemangiomas.

Sources: Combined therapy for complicated hemangiomas

Health professional · Benign Tumors / Infantile Hemangioma / Treatment of infantile hemangioma

Propranolol therapy

Source: Childhood Vascular Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 17, 2025. Captured 2026-09-09.

Propranolol, a nonselective beta-blocker, is first-line therapy for infantile hemangiomas. Early studies suggested that propranolol might act through inducing vasoconstriction and/or by decreasing expression of VEGF and bFGF, leading to apoptosis.[87,88] Subsequent studies indicate that the activity of propranolol for infantile hemangiomas is not secondary to beta blockade resulting from action of the S(-) enantiomer of propranolol but rather resulting from the ability of the R(+) enantiomer of propranolol to inhibit SOX18, a transcription factor that acts as a master regulator of vasculogenesis.[89-91] The R(+) enantiomer interferes with transcriptional activation by SOX18, disrupts SOX18-chromatin binding dynamics, and inhibits SOX18 dimer formation. These biochemical effects result in inhibition of hemangioma stem cell differentiation into endothelial cells and in inhibition of vasculogenesis.[91]

Sources: 87 · 88 · 89 · 91 · 91

The use of propranolol was first noted in two infants treated for cardiac issues in Europe. A change in color, softening, and decrease in hemangioma size was noted. Since that time, the results of a randomized controlled trial have been reported.[92] In 2014, the U.S. Food and Drug Administration (FDA) approved Hemangeol, the pediatric formulation of propranolol hydrochloride, for the treatment of proliferating infantile hemangiomas. Generic propranolol remains in common use.

Sources: 92

There are many other published reports about the efficacy and safety of propranolol.[93-97] Lack of response to treatment is rare. Propranolol therapy is usually used during the proliferative phase but has been effective in patients older than 12 months with infantile hemangiomas.[98]; [99][Level of evidence C3]

Sources: 93 · 97 · 98 · 99 · Level of evidence C3

Evidence (propranolol therapy):

In a large industry-sponsored randomized trial, 456 infants aged 5 weeks to 5 months with proliferating infantile hemangiomas of at least 1.5 cm received either a placebo or propranolol (1 mg/kg per day or 3 mg/kg per day) for 3 or 6 months. After interim analysis of the first 188 patients who completed 24 weeks of trial treatment, the regimen of 3 mg/kg per day for 6 months was selected for the final efficacy analysis.[92][Level of evidence B3]

Sources: 92 · Level of evidence B3

In a large industry-sponsored randomized trial, 456 infants aged 5 weeks to 5 months with proliferating infantile hemangiomas of at least 1.5 cm received either a placebo or propranolol (1 mg/kg per day or 3 mg/kg per day) for 3 or 6 months. After interim analysis of the first 188 patients who completed 24 weeks of trial treatment, the regimen of 3 mg/kg per day for 6 months was selected for the final efficacy analysis.[92][Level of evidence B3]

Of patients who received the selected regimen, 88% showed improvement by week 5, compared with 5% of patients who received the placebo.

Adverse events occurred infrequently.

A retrospective study of 635 infants with infantile hemangiomas who were treated with propranolol (2 mg/kg per day) had the following results:[97][Level of evidence C3]

Sources: 97 · Level of evidence C3

A retrospective study of 635 infants with infantile hemangiomas who were treated with propranolol (2 mg/kg per day) had the following results:[97][Level of evidence C3]

The overall response rate was 91%, with most patients demonstrating regression.

Two percent of patients had side effects, none of which were severe.

A meta-analysis that evaluated 5,130 patients from 61 studies concluded that propranolol was more effective and safer than were other treatments for infantile hemangioma.[100]

Sources: 100

Airway infantile hemangioma lesions are rare. A meta-analysis of 61 patients reported the following results:[101]

Sources: 101

Airway infantile hemangioma lesions are rare. A meta-analysis of 61 patients reported the following results:[101]

There was a trend in decreased treatment failure with increased dosing strategies, which is consistent with the use of higher doses of propranolol in these patients (3 mg/kg per day).

The analysis also suggested that the concurrent use of steroids and propranolol may have reduced efficacy in patients with segmental airway hemangiomas, but prior treatment with steroids had no deleterious effect.

Additional prospective studies are needed to validate these findings.

Diffuse (segmental) hemangiomas of the airway are very rare, and their clinical behavior is different from that of isolated airway lesions.

Intralesional administration of propranolol has been used for periorbital lesions in a limited capacity and showed no advantages over oral administration.[102][Level of evidence B3]

Sources: 102 · Level of evidence B3

Several expert consensus panel recommendations have been reported, including recommendations from the FDA and the European Medicines Agency after a randomized controlled trial of oral propranolol in infantile hemangioma patients led to FDA approval.[103-105]

Sources: 103 · 105

Considerations for the use of propranolol include the following:[103,105,106]

Sources: 103 · 105 · 106

Initiation of treatment: Guidance from consensus panels suggested that treatment should be undertaken in consultation with a pediatric vascular anomaly specialist with expertise in the diagnosis and treatment of pediatric vascular tumors and in the use of propranolol in children. They suggested that hospitalization for initiation of oral propranolol be considered in the following circumstances:[103]The pretreatment evaluation (inpatient or outpatient) includes the following:

Sources: 103

Initiation of treatment: Guidance from consensus panels suggested that treatment should be undertaken in consultation with a pediatric vascular anomaly specialist with expertise in the diagnosis and treatment of pediatric vascular tumors and in the use of propranolol in children. They suggested that hospitalization for initiation of oral propranolol be considered in the following circumstances:[103]The pretreatment evaluation (inpatient or outpatient) includes the following:

Infant aged 4 weeks or younger (corrected for gestational age).

Infant of any age with inadequate social support.

Infant of any age with comorbid conditions affecting the cardiovascular or respiratory system, including symptomatic airway infantile hemangiomas.

Infant of any age with conditions affecting blood glucose maintenance.

History, with focus on cardiovascular and respiratory abnormalities (e.g., poor feeding, dyspnea, tachypnea, diaphoresis, wheezing, heart murmur) and family history of heart block or arrhythmia.

Physical examination, including cardiac and pulmonary assessment and measurement of heart rate.

No need for echocardiogram or electrocardiogram for standard-risk patients. Two studies found no contraindication to beta-blocker therapy in 6.5% to 25% of patients who had electrocardiogram abnormalities.[106,107] Electrocardiogram should be considered in children with heart rate lower than normal for age and history of arrhythmia or arrhythmia detected during examination.

Sources: 106 · 107

Family history of congenital heart disease or maternal history of connective tissue disease.

Dosing: According to the consensus panels, the dosing used is generally 1 mg/kg per day to 3 mg/kg per day divided into two or three doses. The starting dose varies depending on risk factors and location of initiation. Outpatients and inpatients are initially started at a dose of 0.5 mg/kg per day to 1 mg/kg per day and increased over time.[104-106] A retrospective review of initial dosing indicates a starting dose of 2 mg/kg may also be well tolerated. This initial dosing could decrease the need for up-titration and more frequent clinic visits, although prospective studies are needed.[108] Initially, dosing of three times per day is recommended for infants younger than 5 weeks and for patients with PHACE syndrome.[47,103]

Sources: 104 · 106 · 108 · 47 · 103

Monitoring: Monitoring varies depending on the institution. However, oral propranolol peaks at 1 to 3 hours after administration and most centers measure heart rate and blood pressure 1 and 2 hours after each dose with initiation and then when the dose is increased by at least 0.5 mg/kg per day. Parent and patient education includes when to withhold the medication, signs of hypoglycemia, feeding necessity through the night, and when to call the physician with issues, such as illness, that may interfere with oral intake or lead to dehydration or respiratory problems.A large retrospective multicenter study assessed the safety of outpatient administration of propranolol and evaluated the need for monitoring. In this study, 783 patients with 1,148 office visits were evaluated. No symptomatic bradycardia or hypotension was noted. Blood pressure evaluation was unreliable. The results suggested that outpatient evaluation may not be necessary for standard-risk patients with infantile hemangiomas.[109]

Sources: 109

Contraindications: Propranolol treatment is contraindicated in infants and children with the following:[103-105]

Sources: 103 · 105

Contraindications: Propranolol treatment is contraindicated in infants and children with the following:[103-105]

Sinus bradycardia.

Hypotension.

Heart block greater than first degree.

Heart failure.

Asthma.

Hypersensitivity.

PHACE syndrome. PHACE syndrome with CNS arterial disease and/or coarctation of the aorta may be a relative contraindication. A retrospective multi-institutional study that investigated the safety of propranolol therapy for patients with PHACE syndrome identified 76 infants, including 12 patients who were at high risk of having a stroke.[110] The incidence of adverse events in these patients was similar to the incidence in 726 infants who received oral propranolol therapy for hemangioma but did not meet the criteria for PHACE syndrome. A decision to treat should be made in consultation with neurology/neurosurgery and cardiology.

Sources: 110

Adverse effects of propranolol include the following:[111]These complications have been reported in several studies, and severe complications have been rare.[111,113] The risk of these complications is increased in patients with comorbidities and concomitant diseases, including diarrhea, vomiting, and respiratory infections. The need for close monitoring and possible periods of drug discontinuation should be considered during periods of illness.A retrospective review of 1,260 children with infantile hemangiomas who were treated with propranolol identified 26 patients (2.1%) with side effects that required discontinuation of propranolol.[114] Severe sleep disturbance was the most common reason for propranolol cessation, accounting for 65.4% of cases. In total, 23 patients received atenolol and 3 patients received prednisolone as second-line therapy. In the multivariate analysis, only younger age (95% confidence interval [CI], 1.201–2.793; P = .009) and lower body weight (95% CI, 1.036–1.972; P = .014) were associated with intolerable side effects.

Sources: 111 · 111 · 113 · 114

Adverse effects of propranolol include the following:[111]These complications have been reported in several studies, and severe complications have been rare.[111,113] The risk of these complications is increased in patients with comorbidities and concomitant diseases, including diarrhea, vomiting, and respiratory infections. The need for close monitoring and possible periods of drug discontinuation should be considered during periods of illness.A retrospective review of 1,260 children with infantile hemangiomas who were treated with propranolol identified 26 patients (2.1%) with side effects that required discontinuation of propranolol.[114] Severe sleep disturbance was the most common reason for propranolol cessation, accounting for 65.4% of cases. In total, 23 patients received atenolol and 3 patients received prednisolone as second-line therapy. In the multivariate analysis, only younger age (95% confidence interval [CI], 1.201–2.793; P = .009) and lower body weight (95% CI, 1.036–1.972; P = .014) were associated with intolerable side effects.

Hypoglycemia.One study in Japan monitored hypoglycemia in infants with infantile hemangiomas who started treatment with propranolol.[112] After treatment with propranolol, the incidences of severe hypoglycemia and hypoglycemic convulsions were approximately 0.54% and 0.35%, respectively. The incidence of hypoglycemic convulsions appeared to be higher in Japan than in Western countries. Severe hypoglycemia was common in infants younger than 1 year when propranolol was used for 6 months or longer. Severe hypoglycemia often developed from 5:00 AM to 9:00 AM, and it was frequently associated with prolonged periods of fasting, poor feeding, or poor physical conditions.

Sources: 112

Hypotension.

Bradycardia.

Sleep disturbance.

Diarrhea/constipation.

Cold extremities.

Duration of treatment: There are no consensus guidelines for the treatment duration of propranolol. In a prospective, multi-institutional study that assessed efficacy and safety of propranolol in high-risk patients, the administration of propranolol for a minimum of 6 months, up to a maximum of age 12 months, increased treatment success; dosing of propranolol was 3 mg/kg per day. Treatment results were sustained for up to 3 months after discontinuation of therapy. Efficacy and safety of propranolol in this study were similar to those reported in other studies.[115]

Sources: 115

Rebound growth after propranolol therapy: Rebound refers to the growth of infantile hemangiomas after propranolol cessation. A multi-institutional, retrospective review of 997 patients with infantile hemangiomas found a rebound rate of 25.3% in 912 patients with adequate data. On univariate analysis, the factors associated with rebound included discontinuation of treatment before age 9 months, female sex, location on the head or neck, segmental pattern, and deep or mixed skin involvement. On multivariate analysis, only deep infantile hemangiomas and female sex were significantly related.[116] A single-center retrospective review examined 198 patients with infantile hemangioma who underwent oral propranolol therapy. The study reported 35 patients (18%) with rebound growth 1 to 3 months after discontinuation of propranolol treatment. Of the 35 patients, 23 were re-treated with propranolol for up to 3 months. All patients had good responses.[117][Level of evidence C3]

Sources: 116 · 117 · Level of evidence C3

Late growth of infantile hemangiomas: Hemangioma growth can occur in patients older than 3 years, and growth as late as age 8.5 years has been reported. Associated risk factors include segmental morphology, large hemangiomas, PHACE syndrome, and deep cutaneous and subcutaneous lesions in the head and neck.[118,119]

Sources: 118 · 119

Health professional · Benign Tumors / Infantile Hemangioma / Treatment of infantile hemangioma

Selective and other beta-blocker therapy

Source: Childhood Vascular Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 17, 2025. Captured 2026-09-09.

Because of the nonselective and lipophilic nature of propranolol and its ability to cross the blood-brain barrier, other beta-blockers are being used for the treatment of infantile hemangiomas.

Evidence (beta-blocker therapy):

In two small comparison studies, there was no difference in efficacy between propranolol and atenolol.[120,121]

Sources: 120 · 121

In support of a previous retrospective study, a prospective double-blind study compared nadolol with propranolol in 71 infants (aged 1–6 months).[122][Level of evidence A3]

Sources: 122 · Level of evidence A3

In support of a previous retrospective study, a prospective double-blind study compared nadolol with propranolol in 71 infants (aged 1–6 months).[122][Level of evidence A3]

The study demonstrated noninferiority with respect to efficacy and treatment.

A prospective study of 76 infants treated with atenolol noted efficacy and safety similar to propranolol.[123][Level of evidence C3]

Sources: 123 · Level of evidence C3

In one published report, nadolol was associated with the death of an infant (aged 17 weeks) after 10 days of no stool output.[124] There is limited information about the pharmacokinetics and safety of nadolol in infants. The drug has a narrow therapeutic index, and it is excreted and remains unchanged in the feces. If an infant is given nadolol, it is critical to monitor for regular stool output.

Sources: 124

Additional studies are needed to assess differences between the toxicities of these agents and the toxicities of propranolol.

There is some suggestion that the more selective beta-blockers have fewer side effects.[125] A study has suggested that the R(+) enantiomer of propranolol, carried over in drug synthesis rather than the anti–beta-adrenergic L(-) enantiomer (commercially available drug is a racemic mixture), may carry the therapeutic anti-infantile hemangioma effect.[89,90]

Sources: 125 · 89 · 90

Health professional · Benign Tumors / Infantile Hemangioma / Treatment of infantile hemangioma

Corticosteroid therapy

Source: Childhood Vascular Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 17, 2025. Captured 2026-09-09.

Before propranolol, corticosteroids were the first line of treatment for infantile hemangiomas. They were first used in the late 1950s but were never approved by the U.S. FDA for this indication. Corticosteroid therapy has become less popular because of the acute and long-term side effects of steroids (gastrointestinal irritability, immunosuppression, adrenocortical suppression, cushingoid features, and growth failure).

Corticosteroids (prednisone or methylprednisolone) are used at times when there is a contraindication to beta-blocker therapy or as initial treatment while a patient is started on beta-blocker therapy.[126]

Sources: 126

Health professional · Benign Tumors / Infantile Hemangioma / Treatment of infantile hemangioma

Topical beta-blocker therapy

Source: Childhood Vascular Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 17, 2025. Captured 2026-09-09.

Topical beta-blockers are used mainly for the treatment of small, localized, superficial hemangiomas as an alternative to observation. They have also been used in combination with systemic therapy in complicated hemangiomas or to prevent rebound in hemangiomas being tapered off of systemic treatment.[127-129] The same precautions (assessment of comorbidities and family history), as noted previously for propranolol, should be followed for topical beta-blockers. Systemic absorption (plasma and urine) of timolol is variable and prescreening for normal cardiac, pulmonary, and endocrine issues are essential. Recent medical histories and physical examinations are also important. Cautious administration is necessary for ulcerated and deep hemangiomas because higher plasma concentrations of timolol can be seen.[130,131]

Sources: 127 · 129 · 130 · 131

The topical timolol that is used is the ophthalmic gel-forming solution 0.5%. One drop is applied to the hemangioma two times per day until stable response is achieved.

This treatment has limited side effects, but infants with a postmenstrual age of younger than 44 weeks and weight at treatment initiation of less than 2,500 grams may be at risk of adverse events, including bradycardia, hypotension, apnea, and hypothermia.[131,132] Close monitoring of temperature, blood pressure, and heart rate in premature and low birth weight infants with infantile hemangiomas at initiation of and during therapy with topical timolol is necessary.

Sources: 131 · 132

Evidence (topical timolol therapy):

A retrospective cohort study included 666 patients with infantile hemangioma who were treated with topical timolol for 12 months.[133]

Sources: 133

A retrospective cohort study included 666 patients with infantile hemangioma who were treated with topical timolol for 12 months.[133]

Of these patients, 583 (87.5%) had visible reductions in the size of their lesions.

A total of 188 children (28.2%) had excellent responses (no remaining visible abnormality), 127 of whom had complete responses earlier than 12 months.

Of the remaining patients, 292 (43.8%) had good outcomes (i.e., the hemangioma was less than half its original size), while 103 (15.5%) had fair outcomes (i.e., a visibly smaller hemangioma but not less than half its original size), and 83 (12.5%) had poor outcomes (i.e., there was no change in hemangioma size or it was larger).

Patients aged 3 months and younger were more likely to have better outcomes than those older than 3 months (P < .001).

Patients with small infantile hemangiomas (maximum diameter, 1.5–≤5 cm) also had better outcomes than those with large infantile hemangiomas (5–≤10 cm) (P = .046).

In a multicenter, retrospective, cohort study, 731 children with predominantly superficial hemangiomas were treated with topical timolol 0.5% twice daily.[129]

Sources: 129

In a multicenter, retrospective, cohort study, 731 children with predominantly superficial hemangiomas were treated with topical timolol 0.5% twice daily.[129]

Ninety-two percent of patients showed significant improvement in hemangioma color.

Seventy-seven percent of patients showed improvement in hemangioma size, extent, and volume.

Topical timolol is generally well tolerated; however, data on its safety are limited.

A Spanish consortium performed a prospective randomized trial to evaluate the efficacy and safety of topical timolol for the treatment of infantile hemangioma in the early proliferative stage.[134] This multicenter, randomized, double-blind, placebo-controlled, phase IIa pilot clinical trial included patients aged 10 to 60 days with focal or segmental hemangiomas (superficial, deep, mixed, or minimal/arrested growth). Patients were randomly assigned to treatment with either topical timolol maleate solution, 0.5%, or placebo, twice daily for 24 weeks.

Sources: 134

A Spanish consortium performed a prospective randomized trial to evaluate the efficacy and safety of topical timolol for the treatment of infantile hemangioma in the early proliferative stage.[134] This multicenter, randomized, double-blind, placebo-controlled, phase IIa pilot clinical trial included patients aged 10 to 60 days with focal or segmental hemangiomas (superficial, deep, mixed, or minimal/arrested growth). Patients were randomly assigned to treatment with either topical timolol maleate solution, 0.5%, or placebo, twice daily for 24 weeks.

At 24 weeks, there were no significant differences between the timolol treatment and the placebo for complete or nearly complete infantile hemangioma resolution (42% for timolol [n = 11] vs. 36% for placebo [n = 11]; P = .37).

Health professional · Benign Tumors / Infantile Hemangioma / Treatment of infantile hemangioma

Combined therapy for complicated hemangiomas

Source: Childhood Vascular Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 17, 2025. Captured 2026-09-09.

Combined therapy is considered either at initiation of treatment in complicated lesions in which there is functional impairment or organ compromise or used at the end of systemic therapy to prevent hemangioma rebound. Further investigation of efficacy and safety is needed for these regimens.

Evidence (combined therapy for complicated hemangiomas):

A prospective randomized study that compared propranolol and 2 weeks of steroid therapy with propranolol alone revealed the following:[135]

Sources: 135

A prospective randomized study that compared propranolol and 2 weeks of steroid therapy with propranolol alone revealed the following:[135]

Decreased sizes of hemangiomas at 2, 4, and 8 weeks in the combined-therapy group but no statistical difference in the sizes at 6 months.

A prospective randomized study that compared timolol and propranolol with propranolol alone reported the following:[136]

Sources: 136

A prospective randomized study that compared timolol and propranolol with propranolol alone reported the following:[136]

Decreased color of the infantile hemangiomas in the timolol group but no difference in overall sizes of the infantile hemangiomas between the two treatment groups.

Other studies have supported this combination.[137,138][Level of evidence C3]

Sources: 137 · 138 · Level of evidence C3

Health professional · Benign Tumors / Infantile Hemangioma

Treatment options under clinical evaluation for infantile hemangiomas

Source: Childhood Vascular Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 17, 2025. Captured 2026-09-09.

Information about National Cancer Institute (NCI)–supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.

Sources: NCI website · ClinicalTrials.gov website

In response to the COVID-19 pandemic, the Hemangioma Investigator Group is studying the administration of propranolol for low-risk and standard-risk patients through virtual visits.[139]

Sources: 139

Health professional · Benign Tumors / Spindle Cell Hemangioma

Treatment of spindle cell hemangioma

Source: Childhood Vascular Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 17, 2025. Captured 2026-09-09.

There is no standard treatment for spindle cell hemangioma because it has not been studied in clinical trials. Surgical removal is usually curative, although there is a risk of recurrence.[174,175]

Sources: 174 · 175

Health professional · Benign Tumors / Epithelioid Hemangioma

Treatment of epithelioid hemangioma

Source: Childhood Vascular Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 17, 2025. Captured 2026-09-09.

There is no standard treatment for epithelioid hemangioma because it has not been studied in clinical trials. Treatment usually consists of curettage, sclerotherapy, or resection. In rare cases, radiation therapy may be used.[174,178]

Sources: 174 · 178

Health professional · Benign Tumors / Pyogenic Granuloma (Lobular Capillary Hemangioma)

Treatment of pyogenic granuloma

Source: Childhood Vascular Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 17, 2025. Captured 2026-09-09.

Full-thickness excision is the treatment with the lowest recurrence rate (around 3%),[185] but curettage, laser photocoagulation, or cryotherapy can also be used.[186] Topical timolol and propranolol have also been used.

Sources: 185 · 186

Evidence (topical beta-blockers):

In a single-arm series of patients with acquired ocular pyogenic granulomas, a small number of pediatric patients were treated for 21 days to 6 weeks with twice-daily topical timolol, 0.5%.[187,188][Level of evidence C3]

Sources: 187 · 188 · Level of evidence C3

In a single-arm series of patients with acquired ocular pyogenic granulomas, a small number of pediatric patients were treated for 21 days to 6 weeks with twice-daily topical timolol, 0.5%.[187,188][Level of evidence C3]

Complete or near-complete responses without subsequent recurrence or progression were noted in 75% to 100% of the patients (all ages).

A study of 22 patients with cutaneous pyogenic granulomas who were treated with topical 1% propranolol ointment with occlusion had the following results:[189]

Sources: 189

A study of 22 patients with cutaneous pyogenic granulomas who were treated with topical 1% propranolol ointment with occlusion had the following results:[189]

Fifty-nine percent of patients achieved complete responses (mean, 66 days), 18% of patients had stable disease, and 22% of patients did not respond to the treatment.

In this study, only skin toxicity was assessed.

The authors did not comment on the penetrance of the propranolol formulation or include a safety evaluation of the side effects such as hypoglycemia and the effects on heart rate or blood pressure.

Health professional · Benign Tumors / Angiofibroma

Treatment of angiofibroma

Source: Childhood Vascular Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 17, 2025. Captured 2026-09-09.

Excision of the tumor, laser treatments, and topical treatments, such as sirolimus, have been used.[190-192]

Sources: 190 · 192

Evidence (topical sirolimus):

A prospective, randomized, placebo-controlled trial of nine cancer centers that included 62 patients who received sirolimus gel demonstrated the following results:[193]

Sources: 193

A prospective, randomized, placebo-controlled trial of nine cancer centers that included 62 patients who received sirolimus gel demonstrated the following results:[193]

Sixty percent of patients who received sirolimus showed significant improvement in the size and color of the lesion, which was assessed at week 12.

In another prospective, multicenter, randomized, double-blind, vehicle-controlled study that included six monthly clinic visits, 179 patients with tuberous sclerosis complex–related facial angiofibromas were treated with topical rapamycin (sirolimus) 0.3 g per 30 g (1%).[194]

Sources: 194

In another prospective, multicenter, randomized, double-blind, vehicle-controlled study that included six monthly clinic visits, 179 patients with tuberous sclerosis complex–related facial angiofibromas were treated with topical rapamycin (sirolimus) 0.3 g per 30 g (1%).[194]

According to the Angiofibroma Grading Scale, patients who were treated with topical rapamycin showed a statistically and clinically significant improvement in facial angiofibromas.

Health professional · Benign Tumors / Juvenile Nasopharyngeal Angiofibroma

Treatment of juvenile nasopharyngeal angiofibroma

Source: Childhood Vascular Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 17, 2025. Captured 2026-09-09.

Surgical excision is the treatment of choice, but this can be challenging because of the extent of the lesion. A single-institution retrospective review of juvenile nasopharyngeal angiofibromas identified 37 patients with lateral extension.[199] Anterior lateral extension to the pterygopalatine fossa occurred in 36 patients (97%) and further to the infratemporal fossa in 20 patients (54%). In 16 patients (43%), posterior lateral spread was observed (posterior to the pterygoid process and/or between its plates). The recurrence rate was 29.7% (11 of 37 patients). The recurrence rate in patients with anterior and/or posterior lateral extension was significantly higher than in patients with anterior lateral extension only.

Sources: 199

Juvenile nasopharyngeal angiofibromas have also been treated with radiation therapy, chemotherapy, alpha-interferon therapy, and sirolimus.[200-204]

Sources: 200 · 204

Health professional · Intermediate Tumors (Locally Aggressive) / Kaposiform Hemangioendothelioma and Tufted Angioma

Treatment of kaposiform hemangioendothelioma and tufted angioma

Source: Childhood Vascular Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 17, 2025. Captured 2026-09-09.

Health professional · Intermediate Tumors (Locally Aggressive) / Kaposiform Hemangioendothelioma and Tufted Angioma / Treatment of kaposiform hemangioendothelioma and tufted angioma

Treatment of uncomplicated kaposiform hemangioendothelioma and tufted angioma

Source: Childhood Vascular Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 17, 2025. Captured 2026-09-09.

There is no evidence-based standard of care for kaposiform hemangioendotheliomas and tufted angiomas. Treatment varies according to size, location, presence of symptoms, and severity of coagulopathy.

Treatment options for uncomplicated kaposiform hemangioendotheliomas and tufted angiomas include the following:

Observation.

Surgical excision.

Pulse-dye laser.

Topical agents.

Propranolol.

Sirolimus with or without steroid therapy.

Observation is an option for patients with low-risk tumors (i.e., no Kasabach-Merritt phenomenon, small tumor size, asymptomatic). Spontaneous regression and/or stability has been noted.[16]

Sources: 16

Kaposiform hemangioendotheliomas and tufted angiomas that are uncomplicated and localized can be treated with surgical excision, pulse-dye laser, or topical agents (steroids, sirolimus, or tacrolimus).[16-18]

Sources: 16 · 18

Propranolol therapy has been reported as a treatment option for patients with kaposiform hemangioendotheliomas based on positive results of propranolol use for other more benign vascular tumors. Results have been mixed, with a report of improved effectiveness using higher doses of propranolol.[19,20] Preliminary results indicate that propranolol should be reserved for patients with kaposiform hemangioendotheliomas without Kasabach-Merritt phenomenon and with smaller, less complicated lesions.

Sources: 19 · 20

Health professional · Intermediate Tumors (Locally Aggressive) / Kaposiform Hemangioendothelioma and Tufted Angioma / Treatment of kaposiform hemangioendothelioma and tufted angioma

Treatment of complicated kaposiform hemangioendothelioma and tufted angioma

Source: Childhood Vascular Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 17, 2025. Captured 2026-09-09.

Patients who have Kasabach-Merritt phenomenon and/or functional compromise and are symptomatic need aggressive therapy. An American and Canadian multidisciplinary expert panel published guidelines for the management of complicated kaposiform hemangioendotheliomas.[21] A number of treatment therapies have been reported but none have been uniformly effective.[22,23]

Sources: 21 · 22 · 23

Treatment options for complicated kaposiform hemangioendotheliomas and Kasabach-Merritt phenomenon include the following:

Vincristine with or without steroid therapy.

Sources: Vincristine with or without steroid therapy

Sirolimus with or without steroid therapy.

Sources: Sirolimus with or without steroid therapy

Surgical excision.

Sources: Surgical excision

Health professional · Intermediate Tumors (Locally Aggressive) / Kaposiform Hemangioendothelioma and Tufted Angioma / Treatment of kaposiform hemangioendothelioma and tufted angioma / Treatment of complicated kaposiform hemangioendothelioma and tufted angioma

Vincristine with or without steroid therapy

Source: Childhood Vascular Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 17, 2025. Captured 2026-09-09.

The most common treatment option for complicated kaposiform hemangioendotheliomas with or without Kasabach-Merritt phenomenon has traditionally been steroid therapy with or without vincristine or other agents.[21-26] However, many institutions are now using the mTOR inhibitor sirolimus, with or without steroid therapy, as primary treatment for high-risk patients.[27-31] Steroid therapy has not been effective as a single agent for complicated kaposiform hemangioendotheliomas, even at high doses. Patients treated with steroid therapy have a response rate of 10% to 20% and a significant number of side effects.[21]

Sources: 21 · 26 · 27 · 31 · 21

Vincristine was shown to have a hematologic response and reduction in tumor volume in patients with high-risk kaposiform hemangioendotheliomas.[22] Furthermore, in a retrospective review of 37 children with kaposiform hemangioendotheliomas whose lesions did not respond to steroids, 26 of the lesions achieved complete remission, with platelet counts reaching normal levels within 7.6 (± 5.2) weeks after vincristine treatment.[24][Level of evidence C3] Vincristine monotherapy in other studies has not been shown to be effective.[27,31] Successful management of patients with kaposiform hemangioendotheliomas who were treated with vincristine and ticlopidine has also been reported.[32]

Sources: 22 · 24 · Level of evidence C3 · 27 · 31 · 32

In 2013, consensus guidelines for the management of complicated kaposiform hemangioendotheliomas proposed the use of vincristine with or without steroids as first-line therapy. This recommendation was based on available evidence.[21]

Sources: 21

Health professional · Intermediate Tumors (Locally Aggressive) / Kaposiform Hemangioendothelioma and Tufted Angioma / Treatment of kaposiform hemangioendothelioma and tufted angioma / Treatment of complicated kaposiform hemangioendothelioma and tufted angioma

Sirolimus with or without steroid therapy

Source: Childhood Vascular Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 17, 2025. Captured 2026-09-09.

Secondary to promising case reports, case series, and a prospective clinical trial, sirolimus may be considered an alternative first-line therapy for patients with kaposiform hemangioendotheliomas.[28,29,33] There are limited studies investigating the effect of sirolimus on kaposiform hemangioendotheliomas/tufted angiomas without Kasabach-Merritt phenomenon.

Sources: 28 · 29 · 33

Evidence (sirolimus therapy):

In a prospective study that assessed the efficacy and safety of sirolimus for the treatment of complicated vascular anomalies, 13 patients with kaposiform hemangioendotheliomas were treated with sirolimus.[31]

Sources: 31

In a prospective study that assessed the efficacy and safety of sirolimus for the treatment of complicated vascular anomalies, 13 patients with kaposiform hemangioendotheliomas were treated with sirolimus.[31]

In patients with kaposiform hemangioendotheliomas and Kasabach-Merritt phenomenon, ten of ten patients had partial responses, with normalization of their platelet count and fibrinogen at the end of 6 and 12 courses.

Of the three patients with kaposiform hemangioendotheliomas without Kasabach-Merritt phenomenon, two patients experienced partial responses by the end of course 12, and the third patient with multifocal bony disease had disease progression.

Side effects were minimal in this group of young patients, and no patient with a kaposiform hemangioendothelioma required a dose adjustment or was removed from the study because of toxicity of sirolimus.

A retrospective study of sirolimus therapy in patients who had nearly all received previous other treatments reported a complete response rate of 73%. All patients assessed as having Kasabach-Merritt phenomenon had recovery of platelet counts between 1 day and 3 weeks (mean, 1.3 weeks).[34]

Sources: 34

A retrospective study of sirolimus therapy in patients who had nearly all received previous other treatments reported a complete response rate of 73%. All patients assessed as having Kasabach-Merritt phenomenon had recovery of platelet counts between 1 day and 3 weeks (mean, 1.3 weeks).[34]

One death occurred in this study from a respiratory infection in a child with a pleural effusion and multifocal disease involving the thoracic cavity. Biopsy was not routinely used in this study to confirm diagnosis, raising the possibility that this child had an unrecognized complex lymphatic anomaly.

A multicenter, retrospective cohort study analyzed 52 Chinese patients with progressive kaposiform hemangioendotheliomas. Thirty-seven patients (71%) had Kasabach-Merritt phenomenon. Those without Kasabach-Merritt phenomenon received sirolimus alone, and 21 of the patients with Kasabach-Merritt phenomenon received a combination of sirolimus and prednisone.[30]

Sources: 30

A multicenter, retrospective cohort study analyzed 52 Chinese patients with progressive kaposiform hemangioendotheliomas. Thirty-seven patients (71%) had Kasabach-Merritt phenomenon. Those without Kasabach-Merritt phenomenon received sirolimus alone, and 21 of the patients with Kasabach-Merritt phenomenon received a combination of sirolimus and prednisone.[30]

Overall, 96% of patients at 6 months and 98% of patients at 12 months demonstrated improvement in notable symptoms and/or had improved complications.

A single case report of a child with a kaposiform hemangioendothelioma who developed recurrence of pain and fibrosis years after initial therapy and was treated with sirolimus for 26 months observed the following:[33]

Sources: 33

A single case report of a child with a kaposiform hemangioendothelioma who developed recurrence of pain and fibrosis years after initial therapy and was treated with sirolimus for 26 months observed the following:[33]

The patient's contracture and range of motion improved, the lesion shrank, and the child was well 2 years later.

A prospective randomized study of patients with kaposiform hemangioendothelioma associated with Kasabach-Merritt syndrome compared sirolimus monotherapy with sirolimus in combination with prednisolone. The primary outcome was defined as achievement of a durable platelet response (platelet count >100 × 109/L) at week 4.[35][Level of evidence A3]

Sources: 35 · Level of evidence A3

A prospective randomized study of patients with kaposiform hemangioendothelioma associated with Kasabach-Merritt syndrome compared sirolimus monotherapy with sirolimus in combination with prednisolone. The primary outcome was defined as achievement of a durable platelet response (platelet count >100 × 109/L) at week 4.[35][Level of evidence A3]

At week 4, a durable platelet response was achieved in 35 of 37 patients who received sirolimus and prednisolone, compared with 24 of 36 patients who received sirolimus monotherapy (difference, 27.9%; 95% CI, 10.0%–44.7%).

Compared with the sirolimus monotherapy group, the combination treatment group showed improvements in measures of durable platelet responses at all points during the initial 3-week treatment period. The durable platelet responses included median platelet counts during weeks 1 to 4, an increased number of patients achieving fibrinogen stabilization at week 4, and objective lesion responses at 12 months.

The frequencies of total and serious adverse events were similar in both groups.

Patients who received combination therapy had lower total disease sequelae and fewer blood transfusions.

Most high-risk patients (kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon) are treated with sirolimus to achieve serum blood levels of 8 to 15 ng/mL.[30,31,36,37]

Sources: 30 · 31 · 36 · 37

Health professional · Intermediate Tumors (Locally Aggressive) / Kaposiform Hemangioendothelioma and Tufted Angioma / Treatment of kaposiform hemangioendothelioma and tufted angioma / Treatment of complicated kaposiform hemangioendothelioma and tufted angioma

Supportive care and close monitoring of infants on sirolimus

Source: Childhood Vascular Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 17, 2025. Captured 2026-09-09.

A case report described two children with kaposiform hemangioendotheliomas and Kasabach-Merritt syndrome who died of pulmonary infections after treatment with sirolimus.[38] Another child who received sirolimus and prednisolone developed Pneumocystis jirovecii pneumonia.[39] P. jirovecii pneumonia prophylaxis and close monitoring of patients on sirolimus (especially infants) is encouraged.

Sources: 38 · 39

Health professional · Intermediate Tumors (Locally Aggressive) / Kaposiform Hemangioendothelioma and Tufted Angioma / Treatment of kaposiform hemangioendothelioma and tufted angioma / Treatment of complicated kaposiform hemangioendothelioma and tufted angioma

Surgical excision

Source: Childhood Vascular Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 17, 2025. Captured 2026-09-09.

Surgical excision may be possible for lesions that did not respond to medical management or are life threatening. Embolization may be performed in conjunction with surgery or medical therapy; usually, it is a temporizing measure.[40]

Sources: 40

Health professional · Intermediate Tumors (Locally Aggressive) / Kaposiform Hemangioendothelioma and Tufted Angioma / Treatment of kaposiform hemangioendothelioma and tufted angioma / Treatment of complicated kaposiform hemangioendothelioma and tufted angioma

Long-term outcomes

Source: Childhood Vascular Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 17, 2025. Captured 2026-09-09.

Even with therapy, these lesions do not fully regress and can recur. Worsened symptomatology (pain, inflammation) can occur with age, especially around the time of puberty.[41]

Sources: 41

Long-term effects include chronic pain, lymphedema, heart failure, and orthopedic issues.[40,41] These lesions prove to be a difficult dilemma for the practitioner because they have a varied clinical spectrum and response to therapy.

Sources: 40 · 41

Health professional · Intermediate Tumors (Locally Aggressive) / Kaposiform Hemangioendothelioma and Tufted Angioma / Treatment of kaposiform hemangioendothelioma and tufted angioma

Treatment options under clinical evaluation for kaposiform hemangioendothelioma

Source: Childhood Vascular Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 17, 2025. Captured 2026-09-09.

Information about National Cancer Institute (NCI)–supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.

Sources: NCI website · ClinicalTrials.gov website

Health professional · Intermediate Tumors (Rarely Metastasizing) / Pseudomyogenic (Epithelioid Sarcoma–Like) Hemangioendothelioma

Treatment of pseudomyogenic hemangioendothelioma

Source: Childhood Vascular Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 17, 2025. Captured 2026-09-09.

Most patients with pseudomyogenic hemangioendotheliomas are treated with surgery, including amputation for multifocal bony disease.[1] In reported cases, chemotherapy has produced responses.[6,7] Recently, the mammalian target of rapamycin (mTOR) inhibitors have been considered as treatment options.[7,8] An additional case report noted efficacy of sirolimus with the addition of zoledronic acid in a patient with multifocal bony disease.[9] Tyrosine kinase inhibitors (pazopanib and telatinib) have also been used to successfully treat pseudomyogenic hemangioendothelioma.[10,11]

Sources: 1 · 6 · 7 · 7 · 8 · 9 · 10 · 11

Health professional · Intermediate Tumors (Rarely Metastasizing) / Retiform Hemangioendothelioma

Treatment of retiform hemangioendothelioma

Source: Childhood Vascular Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 17, 2025. Captured 2026-09-09.

Treatment for patients with retiform hemangioendotheliomas includes surgical excision with adequate tumor margins and monitoring for local recurrence. There are case reports describing the use of radiation therapy and chemotherapy for inoperable and recurrent tumors.[14-17]

Sources: 14 · 17

Health professional · Intermediate Tumors (Rarely Metastasizing) / Papillary Intralymphatic Angioendothelioma

Treatment of papillary intralymphatic angioendothelioma

Source: Childhood Vascular Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 17, 2025. Captured 2026-09-09.

Surgical excision is the treatment of choice for patients with papillary intralymphatic angioendotheliomas.[20]

Sources: 20

Health professional · Intermediate Tumors (Rarely Metastasizing) / Composite Hemangioendothelioma

Treatment of composite hemangioendothelioma

Source: Childhood Vascular Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 17, 2025. Captured 2026-09-09.

Surgical removal is the treatment of choice for patients with composite hemangioendotheliomas, although radiation therapy and chemotherapy have been used for metastatic disease.[23,24]

Sources: 23 · 24

Health professional · Intermediate Tumors (Rarely Metastasizing) / Kaposi Sarcoma

Treatment of Kaposi sarcoma

Source: Childhood Vascular Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 17, 2025. Captured 2026-09-09.

Children with Kaposi sarcoma have responded to treatment with chemotherapy regimens, including bleomycin, vincristine, and taxanes, although there are no prospective clinical trials. Because Kaposi sarcoma is rare in the pediatric population, there are few evidence-based studies.

Evidence (chemotherapy):

Fifty-six Malawian children aged 3 to 12 years with Kaposi sarcoma were treated with six courses of vincristine, bleomycin, and oral etoposide. This was a high-risk population because 48 of the patients (86%) were HIV positive, 36 of whom (77%) were on antiretroviral therapy (ART).[29][Level of evidence C1]

Sources: 29 · Level of evidence C1

Fifty-six Malawian children aged 3 to 12 years with Kaposi sarcoma were treated with six courses of vincristine, bleomycin, and oral etoposide. This was a high-risk population because 48 of the patients (86%) were HIV positive, 36 of whom (77%) were on antiretroviral therapy (ART).[29][Level of evidence C1]

Eighteen patients (32%) had a complete remission.

At 12 months, the overall survival (OS) rate was 71%, and the event-free survival rate was 50%.

Quality of life improved in 45 patients (80%).

In one retrospective series, 207 children and adolescents with endemic or HIV-related Kaposi sarcoma were treated with unspecified protocols and ART between 2006 and 2015. The study reported a 7-year OS rate of 37% (76 patients). Of these patients, 62% had complete responses, and 8% had stable partial responses. Four of the patients with complete responses had been treated with ART without chemotherapy.[30][Level of evidence C1]

Sources: 30 · Level of evidence C1

Even in adults, the evidence and quality of studies are poor, and it is difficult to recommend particular treatment regimens. Other treatment options have been based on adult studies (refer directly below).

In a systematic review of treatment for classic Kaposi sarcoma, 26 articles published from 1980 to 2010 were reviewed. Articles describing populations at high risk secondary to previous transplant and endemic and epidemic Kaposi sarcoma were excluded.[31] All articles had a minimum of five patients per intervention. A greater than 50% decrease in the size of the lesions or lymphedema was considered a response. The quality of the articles was considered poor, primarily because of lack of uniform staging criteria and variable means of assessing response. The following response rates for systemic treatments were noted:

Sources: 31

Pegylated doxorubicin: 71% to 100%.

Vinca alkaloids: 58% to 90%.

Etoposide: 74% to 76%.

Taxanes: 93% to 100%.

Gemcitabine: 100%.

Vinblastine and bleomycin: 97%.

Interferon alfa-2: 71% to 100%.

For local therapies, the following response rates were reported:

Intralesional vincristine: 62%.

Intralesional interferon alfa-2: 50% to 90%.

Imiquimod: 56%.

Radiation therapy: 63% to 93%.[32-34]

Sources: 32 · 34

For more information about the treatment of Kaposi sarcoma in adults, see Kaposi Sarcoma Treatment.

Sources: Kaposi Sarcoma Treatment

Health professional · Malignant Tumors / Epithelioid Hemangioendothelioma

Treatment of epithelioid hemangioendothelioma

Source: Childhood Vascular Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 17, 2025. Captured 2026-09-09.

Treatment options for epithelioid hemangioendothelioma include the following:

Observation.

Surgery.

Immunotherapy.

Targeted therapy.

Chemotherapy.

Radiation therapy.

For indolent cases, observation is warranted. Surgery is performed when resection is possible. Liver transplant has been used with aggressive liver lesions, both with and without metastases.[3,11-13]

Sources: 3 · 11 · 13

For more aggressive cases, several different drugs have been used, including interferon, thalidomide, sorafenib, pazopanib, and sirolimus.[11,14,15] The most aggressive cases are treated with angiosarcoma-type chemotherapy.

Sources: 11 · 14 · 15

A multi-institutional case series reported on 24 patients aged 2 to 26 years with epithelioid hemangioendothelioma.[8][Level of evidence C2]

Sources: 8 · Level of evidence C2

Three patients who were treated with sirolimus had stable disease or partial responses for more than 2.5 years.

A report from 2020 that investigated sirolimus treatment in children aimed to add to the previous experience of sirolimus in adults. A retrospective review identified six pediatric patients with disseminated epithelioid hemangioendothelioma who were treated with sirolimus.[16]

Sources: 16

Four of the six patients demonstrated partial responses or disease stabilization.

A report from the European paediatric Soft Tissue Sarcoma Study Group analyzed ten patients with localized disease and one patient with metastatic disease from two studies.[17] The median age was 14.3 years (range, 9.0–18.8 years). Local therapy was initial primary surgery in seven patients, and five patients received systemic therapy. No patients received radiation therapy.

Sources: 17

After a median follow-up of 50 months (range, 6–176 months), nine patients remained alive and off therapy and two patients died.

The 5-year progression-free survival rate was 77.1% (95% confidence interval [CI], 34.5%–93.9%).

The 5-year overall survival rate was 74.1% (95% CI, 28.1%–93.0%).

Patients or families who desire additional disease-directed therapy should consider entering trials of novel therapeutic approaches because no standard agents have demonstrated clinically significant activity.

Regardless of whether a decision is made to pursue disease-directed therapy at the time of progression, palliative care remains a central focus of management. This ensures that quality of life is maximized while attempting to reduce symptoms and stress related to the terminal illness.

Health professional · Malignant Tumors / Epithelioid Hemangioendothelioma

Treatment options under clinical evaluation for epithelioid hemangioendothelioma

Source: Childhood Vascular Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 17, 2025. Captured 2026-09-09.

Information about National Cancer Institute (NCI)–supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.

Sources: NCI website · ClinicalTrials.gov website

Health professional · Malignant Tumors / Angiosarcoma

Treatment of angiosarcoma

Source: Childhood Vascular Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 17, 2025. Captured 2026-09-09.

Treatment options for angiosarcoma include the following:

Surgery (localized disease).

Sources: Surgery (localized disease)

Radiation therapy (localized cutaneous disease in adults).

Sources: Radiation therapy (localized cutaneous disease in adults)

Surgery, chemotherapy, and radiation therapy (metastatic disease).

Sources: Surgery, chemotherapy, and radiation therapy (metastatic disease)

Palliative care.

Sources: Palliative care

Health professional · Malignant Tumors / Angiosarcoma / Treatment of angiosarcoma

Surgery

Source: Childhood Vascular Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 17, 2025. Captured 2026-09-09.

Localized disease can be cured by aggressive surgery. Complete surgical excision appears to be crucial for the long-term survival of patients with angiosarcomas and lymphangiosarcomas, despite evidence of tumor shrinkage in some patients who were treated with local or systemic therapy.[21,25-27] Data on liver transplant for localized angiosarcomas are limited.[28][Level of evidence C1]

Sources: 21 · 25 · 27 · 28 · Level of evidence C1

Evidence (surgery):

A review of 222 patients (median age, 62 years; range, 15–90 years) reported the following:[27]

Sources: 27

A review of 222 patients (median age, 62 years; range, 15–90 years) reported the following:[27]

An overall disease-specific survival (DSS) rate of 38% at 5 years.

The 5-year DSS rate was 44% in 138 patients with localized, resected tumors but only 16% in 43 patients with metastases at diagnosis.

One case report suggested that liver transplant may contribute to prolonged disease-free survival.[29][Level of evidence C2]

Sources: 29 · Level of evidence C2

Health professional · Malignant Tumors / Angiosarcoma / Treatment of angiosarcoma

Radiation therapy

Source: Childhood Vascular Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 17, 2025. Captured 2026-09-09.

Localized disease, especially cutaneous angiosarcomas, can be treated with radiation therapy or combined chemotherapy (e.g., paclitaxel) and radiation therapy.[30] Most of these reported cases are in adults.[31] When radiation is used, the doses are high (50–70 Gy), the cutaneous volumes are extensive because of the infiltrating nature of the disease, and regional (draining) nodes are often included, even if clinically negative.[32,33] Because of these factors, radiation therapy is rarely used to treat children.

Sources: 30 · 31 · 32 · 33

Health professional · Malignant Tumors / Angiosarcoma / Treatment of angiosarcoma

Surgery, chemotherapy, and radiation therapy

Source: Childhood Vascular Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 17, 2025. Captured 2026-09-09.

Multimodal treatment with surgery, systemic chemotherapy, and radiation therapy is used for metastatic disease, although it is rarely curative.[33,34] Disease control is the objective in patients with metastatic angiosarcomas. Published progression-free survival is between 3 months and 7 months,[35] and the median overall survival (OS) is 14 to 18 months.[36] In both adults and children, the 5-year OS rates are between 20% and 35%.[21,22,37]

Sources: 33 · 34 · 35 · 36 · 21 · 22 · 37

One child who was diagnosed with angiosarcoma secondary to malignant transformation from infantile hemangioma responded to treatment with bevacizumab (a monoclonal antibody against vascular endothelial growth factor) combined with systemic chemotherapy.[19,34]

Sources: 19 · 34

Biologic agents that inhibit angiogenesis have shown activity in adults with angiosarcomas.[20,37]

Sources: 20 · 37

There is one case report of a pediatric patient with metastatic cardiac angiosarcoma who was successfully treated with conventional chemotherapy, radiation, surgery, and targeted therapies, including pazopanib.[38]

Sources: 38

Health professional · Malignant Tumors / Angiosarcoma / Treatment of angiosarcoma

Palliative care

Source: Childhood Vascular Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 17, 2025. Captured 2026-09-09.

Regardless of whether a decision is made to pursue disease-directed therapy at the time of progression, palliative care remains a central focus of management. This ensures that quality of life is maximized while attempting to reduce symptoms and stress related to the terminal illness.

Health professional · Malignant Tumors / Angiosarcoma

Treatment options under clinical evaluation for angiosarcoma

Source: Childhood Vascular Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 17, 2025. Captured 2026-09-09.

Patients or families who desire additional disease-directed therapy should consider entering trials of novel therapeutic approaches because no standard agents have demonstrated clinically significant activity.

Information about National Cancer Institute (NCI)–supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.

Sources: NCI website · ClinicalTrials.gov website

For patients · Types of childhood vascular tumors / Benign tumors / Infantile hemangioma

Treatment of infantile hemangioma

Source: Childhood Vascular Tumors (PDQ®)–Patient Version, National Cancer Institute.

Source updated: March 6, 2025. Captured 2026-09-09.

Most hemangiomas fade and shrink without treatment. If a hemangioma is large, causing other health problems, or in an area where it could cause serious problems if it grows bigger, treatment may include:

beta-blocker therapy, such as propranolol, nadolol, or atenolol

Sources: beta-blocker · therapy

topical beta-blocker therapy for a hemangioma that is in one area of the skin

Sources: topical

steroid therapy, which may be used when beta-blocker therapy is being started or when beta-blockers cannot be used

Sources: steroid therapy

laser surgery, including pulsed dye laser surgery, which may be used for a hemangioma that has an ulcer or has not completely gone away

Sources: laser surgery

surgery for a hemangioma that has an ulcer, causes vision problems, has not completely gone away, or is on the face and has not responded to other treatment

Sources: responded

combined therapy, such as propranolol and steroid therapy or propranolol and topical beta-blocker therapy

Sources: combined therapy

Learn more about these treatments in Types of treatment for childhood vascular tumors.

Sources: Types of treatment for childhood vascular tumors

For patients · Types of childhood vascular tumors / Intermediate tumors that may spread locally / Kaposiform hemangioendothelioma and tufted angioma

Treatment of kaposiform hemangioendothelioma and tufted angioma

Source: Childhood Vascular Tumors (PDQ®)–Patient Version, National Cancer Institute.

Source updated: March 6, 2025. Captured 2026-09-09.

Kaposiform hemangioendothelioma and tufted angioma are best treated by a vascular anomaly specialist. Treatment depends on the symptoms, size and location of the tumor, and the risk of bleeding. Infection, delay in treatment, and surgery can cause bleeding that is life-threatening.

Sources: specialist

Kaposiform hemangioendothelioma and tufted angioma may be called uncomplicated or complicated.

Uncomplicated tumors are in one area, smaller, cause few or no symptoms, and have a lower risk of bleeding. People with an uncomplicated tumor do not have Kasabach-Merritt phenomenon.

Treatment for uncomplicated kaposiform hemangioendothelioma and tufted angioma may include:

observation for tumors with a low risk of getting worse

surgery to remove the tumor

laser surgery

Sources: laser surgery

topical therapy (steroids or tacrolimus)

Sources: topical · steroids · tacrolimus

beta-blocker therapy (propranolol)

Sources: beta-blocker · propranolol

targeted therapy (sirolimus) with or without steroid therapy

Sources: targeted therapy · sirolimus

Complicated tumors are larger, may cause symptoms, and affect how the body functions. People with a complicated tumor may have Kasabach-Merritt phenomenon, a serious condition that can be life-threatening and requires treatment.

Treatment for complicated kaposiform hemangioendothelioma and tufted angioma may include:

chemotherapy, with or without steroid therapy

Sources: chemotherapy

targeted therapy (sirolimus), with or without steroid therapy

surgery, with or without embolization

Sources: embolization

Even with treatment, these tumors do not fully go away and can come back. Pain and inflammation may get worse with age, often around puberty. Long-term effects include chronic pain, heart failure, bone problems, and lymphedema (the build up of lymph fluid in tissues).

Sources: inflammation · puberty · chronic pain · lymphedema · lymph fluid

Learn more about these treatments in Types of treatment for childhood vascular tumors.

Sources: Types of treatment for childhood vascular tumors

For patients · Types of childhood vascular tumors / Malignant tumors / Epithelioid hemangioendothelioma

Treatment of epithelioid hemangioendothelioma

Source: Childhood Vascular Tumors (PDQ®)–Patient Version, National Cancer Institute.

Source updated: March 6, 2025. Captured 2026-09-09.

Treatment of slow-growing epithelioid hemangioendothelioma may be observation. Surgery may be used when it is possible to remove the tumor.

Treatment of fast-growing epithelioid hemangioendothelioma may include:

surgery to remove the tumor when possible

immunotherapy (interferon) for tumors that are likely to spread

Sources: immunotherapy · interferon

targeted therapy (pazopanib or sirolimus) for tumors that are likely to spread

Sources: targeted therapy · pazopanib · sirolimus

chemotherapy

Sources: chemotherapy

radiation therapy

Sources: radiation therapy

palliative care

Sources: palliative care

Learn more about these treatments in the Types of treatment for childhood vascular tumors.

Sources: Types of treatment for childhood vascular tumors

For patients · Types of childhood vascular tumors / Malignant tumors / Angiosarcoma

Treatment of angiosarcoma

Source: Childhood Vascular Tumors (PDQ®)–Patient Version, National Cancer Institute.

Source updated: March 6, 2025. Captured 2026-09-09.

Treatment of angiosarcoma may include:

surgery to completely remove the tumor

a combination of surgery, chemotherapy, and radiation therapy for angiosarcoma that has spread

Sources: chemotherapy · radiation therapy

palliative care

Sources: palliative care

Learn more about these treatments in Types of treatment for childhood vascular tumors.

Sources: Types of treatment for childhood vascular tumors

For patients

Types of treatment for childhood vascular tumors

Source: Childhood Vascular Tumors (PDQ®)–Patient Version, National Cancer Institute.

Source updated: March 6, 2025. Captured 2026-09-09.

For patients · Types of treatment for childhood vascular tumors

Who treats children with vascular tumors?

Source: Childhood Vascular Tumors (PDQ®)–Patient Version, National Cancer Institute.

Source updated: March 6, 2025. Captured 2026-09-09.

A pediatric oncologist, a doctor who specializes in treating children with cancer, oversees treatment for childhood vascular tumors. The pediatric oncologist works with other health care providers who are experts in treating children with cancer and also specialize in certain areas of medicine. Other specialists may include:

pediatric vascular anomaly specialist (expert in treating children with vascular tumors)

pediatric surgeon

Sources: pediatric surgeon

pediatric dermatologist

pediatric hematologist and oncologist

orthopedic surgeon

Sources: orthopedic surgeon

radiation oncologist

Sources: radiation oncologist

pediatric nurse specialist

Sources: pediatric nurse specialist

rehabilitation specialist

Sources: rehabilitation specialist

psychologist

Sources: psychologist

social worker

Sources: social worker

For patients · Types of treatment for childhood vascular tumors

Treatment options

Source: Childhood Vascular Tumors (PDQ®)–Patient Version, National Cancer Institute.

Source updated: March 6, 2025. Captured 2026-09-09.

There are different types of treatment for children and adolescents with vascular tumors. You and your child's care team will work together to decide treatment. Many factors will be considered, such as where the tumor is located, your child's age and overall health, the type of vascular tumor, the risk of scarring, and the likelihood of completely treating the vascular tumor.

Your child's treatment plan will include information about the tumor, the goals of treatment, treatment options, and the possible side effects. It will be helpful to talk with your child's care team before treatment begins about what to expect. For help every step of the way, see our booklet, Children with Cancer: A Guide for Parents.

Sources: Children with Cancer: A Guide for Parents

Types of treatment your child might have include:

For patients · Types of treatment for childhood vascular tumors / Treatment options

Beta-blocker therapy

Source: Childhood Vascular Tumors (PDQ®)–Patient Version, National Cancer Institute.

Source updated: March 6, 2025. Captured 2026-09-09.

Beta-blockers are drugs commonly used to lower blood pressure and heart rate, but they can also shrink certain types of vascular tumors, such as infantile hemangiomas. Beta-blocker therapy may be injected into a vein, taken by mouth, or placed on the skin (topical). How beta-blocker therapy is given depends on the type of vascular tumor being treated and where it first formed.

Sources: blood pressure · heart rate · topical

The beta-blocker propranolol is usually the first treatment for hemangiomas. Infants younger than 4 weeks, who have an underlying condition, or who are treated with IV propranolol may need to have their treatment started in a hospital. Infantile hemangioma may also be treated with propranolol and steroid therapy or propranolol and topical beta-blocker therapy. Propranolol is also used to treat benign vascular tumors of liver.

Other beta-blockers used to treat vascular tumors include atenolol, nadolol, and timolol.

For patients · Types of treatment for childhood vascular tumors / Treatment options

Surgery

Source: Childhood Vascular Tumors (PDQ®)–Patient Version, National Cancer Institute.

Source updated: March 6, 2025. Captured 2026-09-09.

The following types of surgery may be used to remove many types of vascular tumors:

Excision is surgery to remove the entire tumor and some of the healthy tissue around it.

Laser surgery uses a laser beam (a narrow beam of intense light) as a knife to make bloodless cuts in tissue or remove a skin lesion such as a tumor. Surgery with a pulsed dye laser may be used for some hemangiomas. This type of laser uses a beam of light that targets blood vessels in the skin. The light is changed into heat and the blood vessels are destroyed without damaging nearby skin.

Curettage uses a small, spoon-shaped instrument with a sharp edge called a curette to remove abnormal tissue.

Total hepatectomy and liver transplant removes the entire liver followed by a transplant of a healthy liver from a donor.

Sources: hepatectomy · transplant · donor

Amputation removes an arm or leg when there are multiple tumors in the bone.

The type of surgery used depends on the type of vascular tumor and where it formed in the body.

After the doctor removes all the cancer that can be seen at the time of the surgery, some people may be given chemotherapy or radiation therapy to kill any cancer cells that are left. Treatment given after the surgery to lower the risk that the cancer will come back is called adjuvant therapy.

Sources: chemotherapy · radiation therapy · adjuvant therapy

For patients · Types of treatment for childhood vascular tumors / Treatment options

Photocoagulation

Source: Childhood Vascular Tumors (PDQ®)–Patient Version, National Cancer Institute.

Source updated: March 6, 2025. Captured 2026-09-09.

Photocoagulation is the use of an intense beam of light, such as a laser, to seal off blood vessels or destroy tissue. It is used to treat pyogenic granuloma.

Sources: pyogenic granuloma

For patients · Types of treatment for childhood vascular tumors / Treatment options

Cryotherapy

Source: Childhood Vascular Tumors (PDQ®)–Patient Version, National Cancer Institute.

Source updated: March 6, 2025. Captured 2026-09-09.

Cryotherapy uses an instrument to freeze and destroy abnormal tissue, such as abnormal blood vessels in pyogenic granuloma. This type of treatment is also called cryosurgery.

Sources: Cryotherapy

Learn more about Cryosurgery to Treat Cancer.

Sources: Cryosurgery to Treat Cancer

For patients · Types of treatment for childhood vascular tumors / Treatment options

Embolization

Source: Childhood Vascular Tumors (PDQ®)–Patient Version, National Cancer Institute.

Source updated: March 6, 2025. Captured 2026-09-09.

Embolization uses particles, such as tiny gelatin sponges or beads, to block blood vessels in the liver. It may be used to block blood flow to some benign vascular tumors of the liver and kaposiform hemangioendothelioma.

For patients · Types of treatment for childhood vascular tumors / Treatment options

Chemotherapy

Source: Childhood Vascular Tumors (PDQ®)–Patient Version, National Cancer Institute.

Source updated: March 6, 2025. Captured 2026-09-09.

Chemotherapy (also called chemo) uses drugs to stop the growth of tumor cells. Chemotherapy either kills the cancer cells or stops them from dividing. Chemotherapy may be given alone or with other types of treatment.

For some vascular tumors, chemotherapy is injected into a vein. When given this way, the drugs enter the bloodstream to reach tumor cells throughout the body.

Sources: injected

Chemotherapy drugs that may be used alone or in combination to treat childhood vascular tumors include:

bleomycin

Sources: bleomycin

cyclophosphamide

Sources: cyclophosphamide

etoposide

Sources: etoposide

gemcitabine

Sources: gemcitabine

pegylated doxorubicin

Sources: doxorubicin

vinblastine

Sources: vinblastine

vincristine

Sources: vincristine

Other chemotherapy drugs not listed here may also be used.

Learn more about how chemotherapy works, how it is given, common side effects, and more at Chemotherapy to Treat Cancer.

Sources: Chemotherapy to Treat Cancer

For patients · Types of treatment for childhood vascular tumors / Treatment options

Sclerotherapy

Source: Childhood Vascular Tumors (PDQ®)–Patient Version, National Cancer Institute.

Source updated: March 6, 2025. Captured 2026-09-09.

Sclerotherapy destroys the tumor and the blood vessels that lead to it. A liquid is injected into the blood vessels, causing them to scar and break down. Over time, the destroyed blood vessels are absorbed into normal tissue. The blood flows through nearby healthy veins instead. Sclerotherapy is used to treat epithelioid hemangioma.

For patients · Types of treatment for childhood vascular tumors / Treatment options

Radiation therapy

Source: Childhood Vascular Tumors (PDQ®)–Patient Version, National Cancer Institute.

Source updated: March 6, 2025. Captured 2026-09-09.

Radiation therapy uses high-energy x-rays or other types of radiation to kill tumor cells or keep them from growing. External radiation therapy uses a machine outside the body to send radiation toward the area of the body with the tumor. It is used to treat some vascular tumors.

Sources: External radiation therapy

Learn more about External Beam Radiation Therapy for Cancer and Radiation Therapy Side Effects.

Sources: External Beam Radiation Therapy for Cancer · Radiation Therapy Side Effects

For patients · Types of treatment for childhood vascular tumors / Treatment options

Targeted therapy

Source: Childhood Vascular Tumors (PDQ®)–Patient Version, National Cancer Institute.

Source updated: March 6, 2025. Captured 2026-09-09.

Targeted therapy uses drugs or other substances to block the action of specific enzymes, proteins, or other molecules involved in the growth and spread of cancer cells. Different types of targeted therapy are being used or studied to treat childhood vascular tumors:

pazopanib

Sources: pazopanib

sirolimus

Sources: sirolimus

Learn more about Targeted Therapy to Treat Cancer.

Sources: Targeted Therapy to Treat Cancer

For patients · Types of treatment for childhood vascular tumors / Treatment options

Immunotherapy

Source: Childhood Vascular Tumors (PDQ®)–Patient Version, National Cancer Institute.

Source updated: March 6, 2025. Captured 2026-09-09.

Immunotherapy helps a person's immune system fight cancer. Interferon is a type of immunotherapy used to treat vascular tumors.

Learn more about Immunotherapy to Treat Cancer.

Sources: Immunotherapy to Treat Cancer

For patients · Types of treatment for childhood vascular tumors / Treatment options

Other drug therapy

Source: Childhood Vascular Tumors (PDQ®)–Patient Version, National Cancer Institute.

Source updated: March 6, 2025. Captured 2026-09-09.

Other drugs used to treat childhood vascular tumors or manage their effects include:

Steroid therapy: Steroids are hormones made naturally in the body. They can also be made in a laboratory and used as drugs. Steroid drugs help shrink some vascular tumors. Corticosteroids, such as prednisone and methylprednisolone, are used to treat infantile hemangioma.

Sources: Steroid · hormones

Immunosuppressant therapy: These drugs decrease the body's immune responses. Immunosuppressant therapy has been used to help shrink vascular tumors. Topical tacrolimus is used to treat kaposiform hemangioendotheliomas and tufted angiomas.

Sources: Immunosuppressant therapy

Thyroid hormone replacement therapy: These drugs replace hormones made by the thyroid and are used to treat a rare form of hypothyroidism caused by some vascular tumors, such as liver hemangiomas.

Sources: hypothyroidism

For patients · Types of treatment for childhood vascular tumors / Treatment options

Observation

Source: Childhood Vascular Tumors (PDQ®)–Patient Version, National Cancer Institute.

Source updated: March 6, 2025. Captured 2026-09-09.

Observation is closely monitoring a person's condition without giving any treatment until symptoms appear or change.

For patients · Types of treatment for childhood vascular tumors / Treatment options

Clinical trials

Source: Childhood Vascular Tumors (PDQ®)–Patient Version, National Cancer Institute.

Source updated: March 6, 2025. Captured 2026-09-09.

For some children, joining a clinical trial may be an option. There are different types of clinical trials for childhood cancer. For example, a treatment trial tests new treatments or new ways of using current treatments. Supportive care and palliative care trials look at ways to improve quality of life, especially for those who have side effects from cancer and its treatment.

You can use the clinical trial search to find NCI-supported cancer clinical trials accepting participants. The search allows you to filter trials based on the type of cancer, your child's age, and where the trials are being done. Clinical trials supported by other organizations can be found on the ClinicalTrials.gov website.

Sources: clinical trial search · ClinicalTrials.gov

Learn more about clinical trials, including how to find and join one, at Clinical Trials Information for Patients and Caregivers.

Sources: Clinical Trials Information for Patients and Caregivers

For patients

Side effects and late effects of treatment

Source: Childhood Vascular Tumors (PDQ®)–Patient Version, National Cancer Institute.

Source updated: March 6, 2025. Captured 2026-09-09.

Treatments for vascular tumors can cause side effects. Which side effects your child might have depends on the type of treatment they receive, the dose, and how their body reacts. Talk with your child's treatment team about which side effects to look for and ways to manage them.

To learn more about side effects that begin during treatment for cancer, visit Side Effects.

Sources: side effects · Side Effects

Problems from cancer treatment that begin 6 months or later after treatment and continue for months or years are called late effects. Late effects of treatment may include:

physical problems

changes in mood, feelings, thinking, learning, or memory

second cancers (new types of cancer)

Some late effects may be treated or controlled. It is important to talk with your child's doctors about the possible late effects caused by some treatments. Learn more about Late Effects of Treatment for Childhood Cancer.

Sources: Late Effects of Treatment for Childhood Cancer

Studies

Efficacy and Safety of Sirolimus in Vascular Anomalies That Are Refractory to Standard Care

NCT02638389 · RECRUITING · phase3

Vascular Malformations

ClinicalTrials.gov record

Treatment of Congenital Vascular Malformations Using Sirolimus: Improving Quality of Life

NCT03987152 · UNKNOWN · phase3

Vascular Malformations

ClinicalTrials.gov record

Trametinib in the Treatment of Complicated Extracranial Arterial Venous Malformation

NCT04258046 · COMPLETED · phase2

Venous Malformation, Arterial Disease

ClinicalTrials.gov record

A Study of the Safety and Tolerability in Participants With PIK3CA-related Overgrowth Spectrum or Proteus Syndrome Who Are Being Treated With Miransertib (MK-7075) in Other Studies (MK-7075-006)

NCT04980872 · ACTIVE NOT RECRUITING · phase2

PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS)

ClinicalTrials.gov record

Cobimetinib In Extracranial Arteriovenous Malformations (COBI-AVM Study)

NCT05125471 · COMPLETED · phase2

Arteriovenous Malformations (Extracranial)

ClinicalTrials.gov record

Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.

NCT05948943 · RECRUITING · phase2, phase3

Lymphatic Malformations

ClinicalTrials.gov record

Disease and treatment settings

Childhood Vascular Tumors

Disease and treatment setting

Vascular Tumors in children and adolescents